SCHEMBL96461

SCHEMBL96461

CCOC(=O)C(C(=O)OCC)=C(C)c1ccc(OC)c2[nH]c(=O)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 4/20 0.39
CYP19A1 P11511 3/20 0.38
MEN1 O00255 3/20 0.37
MAPT P10636 3/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
LMNA P02545 2/20 0.37
PLIN1 O60240 1/20 0.37
PLIN5 Q00G26 1/20 0.37
ABHD5 Q8WTS1 1/20 0.37
HSD17B10 Q99714 3/20 0.37
TP53 P04637 1/20 0.37
VKORC1 Q9BQB6 1/20 0.37
HPGD P15428 5/20 0.36
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 2/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862094 0.79 KDM4E (0.45) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL29195984 0.76 KDM4E (0.53) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL11121058 0.75 MAPT (0.43) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL30862093 0.73 KDM4E (0.42) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL97981 0.71 ADRB2 (0.41) NQO2CYP19A1MEN1KMT2APOLB
SCHEMBL11401085 0.71 NQO2 (0.53) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL14438072 0.70 NQO2 (0.61) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL11711731 0.70 ALDH1A1 (0.41) NQO2CYP19A1HSD17B10TP53HPGD
SCHEMBL9653621 0.69 NQO2 (0.47) NQO2CYP19A1MEN1MAPTKMT2A
SCHEMBL98476 0.68 ADRB2 (0.37) NQO2CYP19A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 NQO2 2030/4885CYP19A1 2763/4885MEN1 3912/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 NQO2 2030/4885CYP19A1 2763/4885MEN1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.